Discontinued — last reported Q3 '24
Business Segments · Revenue
Drug Development — Revenue
Labcorp Holdings Drug Development — Revenue increased by 4.3% to $737.70M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 2.6%, from $719.10M to $737.70M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ3 2024
Rolls up toTotal Revenue
How to read this metric
Higher revenue indicates strong demand for outsourced clinical research services and successful contract acquisition.
Detailed definition
This metric tracks the total gross revenue generated by the drug development segment through clinical trial support, lab...
Peer comparison
Standard revenue metric for CRO segments found in large healthcare conglomerates or pure-play clinical research firms.
Metric ID:
lh_segment_drug_development_revenuesHistorical Data
13 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.50B | $1.46B | $1.46B | $677.90M | $666.40M | $648.80M | $661.30M | $699.00M | $719.10M | $694.80M | $710.90M | $707.00M | $737.70M |
| QoQ Change | — | -2.4% | -0.0% | -53.5% | -1.7% | -2.6% | +1.9% | +5.7% | +2.9% | -3.4% | +2.3% | -0.5% | +4.3% |
| YoY Change | — | — | — | -54.7% | -54.3% | — | -54.7% | +3.1% | +7.9% | +7.1% | +7.5% | +1.1% | +2.6% |
Range$648.80M – $1.50B
CAGR-21.0%
Avg YoY Growth-14.9%
Median YoY Growth+2.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's drug development — revenue?
- Labcorp Holdings (LH) reported drug development — revenue of $737.70M in Q3 2024.
- How has Labcorp Holdings's drug development — revenue changed year-over-year?
- Labcorp Holdings's drug development — revenue increased by 2.6% year-over-year, from $719.10M to $737.70M.
- What does drug development — revenue mean?
- The total sales generated by the drug development and clinical research services business unit.